Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay

You'll hear buzz about using the PCSK9 inhibitors, evolocumab (Repatha) or alirocumab (Praluent), in patients with CV disease.

These injectable meds lower LDL cholesterol by about 60%...even in those on a high-intensity statin (atorvastatin 80 mg, etc).

Now evidence suggests that adding evolocumab to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals